Introduction
Bluetongue virus (BTV) is the best studied member of the orbivirus genus in the Reoviridae family. The virus consists of an icosahedral nucleocapsid containing two major and three minor proteins, surrounded by a diffuse outer layer which contains two proteins, VP2 and VP5. VP2 is involved in virus neutralization (Huismans & Erasmus, 1981; ) and purified VP2 has been shown to elicit a protective immune response in sheep (Huismans et al., 1987) . VP5 may provide at least a modulating role in the expression of neutralizing epitopes Mertens et al., 1989) . The actual number of neutralization epitopes on VP2 remains largely undefined. provided evidence for the existence of three distinct neutralizing epitopes on BTV-17 using a limited number of neutralizing monoclonal antibodies (N-MAbs).
Prior studies with polyvalent antisera (Della-Porta et al., 1981a, b; Huismans & Erasmus, 1981) and with MAbs Ristow et al., 1988) have shown neutralization epitopes on one serotype can exist in neutralizing or non-neutralizing forms on other BTV serotypes. In this study we have investigated the ability of seven N-MAbs to an Australian isolate of BTV serotype 1 [BTV-1 (Aust)] to bind to and neutralize 19 different serotypes of BTV and a large number of N-Mab-selected neutralization escape variants to determine both the number of neutralization epitopes on BTV and the extent of their conservation across the serogroup.
(CSIRO154) and and South African attenuated strains of BTV-I to -14. Unless otherwise indicated BTV-1 refers to the Australian isolate of this serotype. Viruses were grown in either Vero or SVP (Eaton et al., 1987) cells.
Preparation of B T V antigen. SVP cells were infected at multiplicities
ranging from 1 to 5 p.f.u./cell. At 24 to 40 h post-infection (p.i.) cells were scraped off, washed once with medium, resuspended in STM (150 mM-NaCI, 10 mM-Tris-HC1 pH 7.4, 1.5 mM-MgC12) and lysed at 0 °C by addition of NP40 to 1%. After 5 rain the nuclear-cytoskeleton fraction was sedimented, resuspended in STM and sheared in a Dounce homogenizer. Nuclei were removed by centrifugation and virus-like particles in the supernatant were pelleted through a 40% sucrose column in STM in a SW41 rotor at 35000 r.p.m, for 1.5 h. Material in the pellet consisted predominantly of structural and non-structural viral protein and was resuspended in 0.01 M-phosphate-buffered saline (PBS) (pH 7-2) for use as the antigen in N-MAb-binding experiments or alternatively resuspended in Hanks' balanced salt solution, mixed with adjuvant and used to inoculate mice for N-MAb production.
Production of MAbs.
All the BTV-specific murine MAbs used in this study except 9J3/G6 were derived from hybridoma cell lines resulting from two separate fusions of the myeloma cell line SP2/0-Agl4 with spleen lymphocytes of BALB/c mice immunized and primed with virus particles derived from the cytoskeleton of BTV-l-infected cells (Eaton et al., 1987) . MAbs were screened by ELISA as previously described (Lunt et al., 1988b) . The hybridoma secreting 9J3/G6 was isolated following fusion of SP2/0-Agl4 cells with spleen cells (Breschkin et al., 1981) from mice inoculated with a 10 K suspension of BTV-1-infected suckling mouse brain in Hanks' balanced salt solution. The hybridoma cell lines secreting MAbs were cloned once by limiting dilution and inoculated into pristane-primed BALB/c mice to produce ascites fluid. MABs were afl]nity-purified from ascites fluid as described elsewhere .
Characterization of MAbs. MAb specificities were determined by radioimmunoprecipitation (Lunt et al., 1988b) and Western blotting ) (see Table 1 ). Only N-MAb 31D8/A12 was positive in the Western blot test and reacted with the outer coat protein VP2 (Fig. 1) . N-MAbs 30E6/G4, 30E3/F4 and 30E10/A11 immunoprecipitated VP2 of BTV-1 (Aust). It had previously been shown that NMAb 9J3/G6 could immunoprecipitate this protein (White et al., 1985) . The specificities of N-MAbs 31A2/D2 and 31D8/AI remained uncertain; although both precipitated VP2, they coprecipitated other virus-specified proteins (results not shown).
Plaque forming inhibition and virus neutralization tests. Confluent Vero cells in 90 mm Petri dishes were infected with 105 p.f.u, of virus and overlaid with agarose. N-MAbs were adsorbed to 5 mm diameter filter paper discs and placed onto the surface of the agarose overlay for 5 days prior to staining with neutral red. Plates were read on the day 6 and 7 p.i.
For the virus microneutralization test, 200 TCID5o units of wild-type and variant viruses were preincubated with a series of twofold dilutions of N-MAb and mixed with Vero cells in duplicate wells of a microtitre tray. Wells were scored for c.p.e. 4 days later. The neutralization titre was defined as the reciprocal of the highest N-MAb dilution that prevented c.p.e, in a least 50% of the cell monolayer in both wells. The difference in N-MAb neutralization titre (in log2 units) between wildtype and variant BTV viruses was used to quantify the degree of resistance to neutralization the variant virus exhibited compared to wild-type virus.
Selection and growth of variant viruses. Stock virus was diluted in PBS containing 1 ~ (w/v) bovine serum albumin (BSA) (PBS-BSA) to a concentration of 2 x 106 p.f.u./ml and mixed with an equal volume of N-MAb diluted 1:2 in PBS-BSA. Following incubation at 37 °C for 1 h, 0-2 ml aliquots were adsorbed to monolayers of SVP cells for 1 h. Three days later, plates were examined microscopically and small areas of cell destruction were marked. After a further 3 day incubation, four or five plaques, approximately 2 to 4 mm in diameter, were picked from marked areas. Variant viruses were incubated with N-MAb and each was adsorbed to cells. Virus was harvested from each flask and log dilutions were made in PBS-BSA. One-hundred ~tl aliquots of diluted virus were incubated at 37 °C for 1 hr with an equal volume of N-MAb, adsorbed to cells and overlaid with agarose. Five days later, several plaques were picked and virus stock was produced in the usual manner. Following a further plaque purification in the absence of N-MAb, stocks of the variant viruses were generated in SVP or Vero cells to produce titres of approximately 5 x l06 p.f.u./ml. Groups of variant viruses isolated using N-MAbs 9J3/G6, 30E3/F4, 30E6/G4, 30E10/A11, 31A2/D2 and 31D8/A1 were designated J3, E3, E6, El0, A2 and D8 respectively. Individual variant viruses were further labelled with a letter of the alphabet.
Quantitative ELISA analysis. Polyvalent rabbit hyperimmune antiserum raised to a cytoskeletal extract of BTV-l-infected cells (Eaton et al., 1987) was adsorbed to the wells of a polyvinyl microtitre tray (Cooke's, Dynatech). Antigen from wild-type or variant virusinfected cells was bound for 1-5 h at 37 °C. N-MAb diluted in PBS plus 0.05 % Tween 20 containing 0-25 % BSA was added in duplicate to each virus preparation. The optimum dilution of each N-MAb used was defined as that yielding an absorbance value which lay in the upper part of the straight line portion of the curve resulting from titration of the N-MAb against BTV-1 in an indirect ELISA (Lunt et al., 1988a; Gerhard et al., 1981) . A BTV serogroup-reactive anti-VP7 N-MAb, 20E9B7G2 (Lunt et al., 1988b) , was included in the assay to act as a positive control and to determine the amount of antigen present for each virus preparation under test. Under the conditions of antigen preparation employed in this assay, the VP7-specific MAb exhibited similar avidity and binding curves for all BTV serotypes except BTV-15 (Aust) and BTV-7 (South Africa). Comparative binding levels for these two serotypes were determined using polyvalent reference antisera. A MAb specific for epizootic haemorrhagic disease of deer virus was incorporated as a negative control. Plates were then processed as previously described (Lunt et al., 1988a) . The extent of binding of a given N-MAb to a particular test virus relative to its binding to a wild-type virus was determined in a similar manner to the method employed by Gerhard et al. (1981) and Garcia-Barreno et al. To determine whether this was so, BTV-1 antigen was titrated against fixed dilutions of the relevant MAb. The ratio of N-MAb absorbance to that of a group-reactive antibody was found to be constant for the six N-MAbs of the panel over an absorbance range of 0.5 to 1.6 for the groupreactive antibody. Thus binding data were deemed acceptable when the amount of antigen bound yielded an A value within this range.
Results

Reaction of N-MAbs with Australian (homologous) and South African isolates of BTV-1
Seven MAbs which neutralized BTV-1 (Aust) in the plaque inhibition and virus microneutralization tests were tested for their ability to neutralize a South African isolate of BTV-1. Only four N-MAbs (30E3/F4, 30E10/A11, 31A2/D2 and 31D8/A1) neutralized BTV-1 (South Africa) ( Table 1) . The results presented in Table 2 indicate however that BTV-1 (South Africa) bound six of the seven N-MAbs. The binding of 9J3/G6 to the South African isolate was markedly reduced. 30E6/G4 bound to but did not neutralize BTV-1 (South Africa).
Reaction of N-MAbs with other BTV serotypes
South African BTV serotypes 2 to 14 and isolates of the seven other known Australian BTV serotypes were tested against the seven N-MAbs in ELISA, plaque inhibition and virus microneutralization tests. No heterologous neutralization was observed. The ELISA results are presented in Table 2 . None of the N-MAbs bound BTV-2 or BTV-15 (Aust) and only two (30E10/All and 31D8/A1) bound BTV-3 (South African and Australian isolates), BTV-13 and BTV-14 at significantly reduced levels compared to BTV-1 (Aust), i.e. homologous binding. BTV-5 bound these two N-MAbs and one other (31A2/D2) with less than 50% efficiency compared to the homologous reaction. Of the remaining serotypes tested, BTV-6, -8, -9 (South Africa), -10, -11 and -21 bound six of the N-MAb panel with varying, but generally high, efficiency. BTV-4, -12, -16 and -23 bound five N-MAbs and BTV-7, -9 (Aust) and -20 bound four N-MAbs. The 30E10/A11 and 31D8/A1 epitopes were the most conserved across the BTV serogroup. Epitopes defined by 31A2/D2 and 31D8/A12 N-MAbs also showed a high level of serogroup conservation and the epitope corresponding to 30E3/F4 showed slightly less. Expression of the 30E6/G4 epitope was more restricted throughout the serogroup and the 9J3/G6 epitope was expressed only on the Australian isolate of BTV-1.
These results indicated that serological differences between BTV serotypes may be attributed, at least partially, to conformational changes in the outer coat proteins of the virus such that conserved epitopes which are present in a neutralizing capacity in one serotype may be available in a non-neutralizing capacity in other serotypes. This suggests that neutralization-resistant variants of BTV-1 (Aust) may still retain an ability to bind N-MAbs used in their selection. To investigate this and to determine the extent of interactions between individual neutralizing epitopes, pools of neutralizationresistant variants of BTV-1 (Aust) were isolated using each of six N-MAbs. The ability of viruses within each variant virus pool to bind both homologous and heterologous N-MAbs was examined by virus neutralization assays and ELISA as described in Methods.
Reaction of N-MAbs with homologous and heterologous variant viruses
The results in Fig. 2 show that in their reactions with all 25 variant viruses, each N-MAb exhibited characteristic reaction properties indicating each was directed towards a unique epitope. The data also revealed that at least half, and in some cases all variants in each pool resisted neutralization with the five heterologous N-MAbs. These results indicate that all the N-MAb-defined epitopes were mutually interactive. Only one variant (E3. F) showed no resistance to neutralization by any of the five heterologous N-MAbs in Fig. 2 (but was mildly resistant to N-MAb 31D8/A12; (data not shown). However, other variants in the same pool, E3. D and E3. E, showed increased resistance to five heterologous N-MAbs, and E3.B to four. For all reactions between variant virus and heterologous N-MAb, D8 variants showed the most consistent resistance to neutralization by all N-MAbs and the exception, D8.A, displayed resistance to all antibodies except 30E3/F4. Apart from D8 variants, E6 variants showed the most pronounced ability to resist neutralization by heterologous N-MAbs, and J3 variants showed the least. For variants within the E6 and E3 pools, resistance to neutralization correlated totally with a failure of the homologous N-MAb to bind the virus (Fig. 2) . However half of the variants in the J3 and A2 pools, four of five in the D8, and all variants in the El0 pools were able to bind their homologous N-MAb (albeit at reduced efficiencies compared to its reaction with wild-type virus) while still resisting neutralization by it. With one variant, E 10. J, homologous N-MAb binding was actually enhanced compared to wild-type virus despite a high resistance to neutralization. As observed with the interaction between some variant virus pools and their homologous N-MAb, there was no consistent correlation between increased resistance to neutralization and failure to bind heterologous antibody. For example, 13 variants showed an increased resistance to neutralization by the heterologous N-MAb 30E3/F4. Five of the variants showed no detectable binding of this antibody. Six variants bound less of this N-MAb than did wild-type virus and two, E10.J and A2. B, were more efficient and as efficient as wild-type virus, respectively, in binding 30E3/F4. Of the 25 variants analysed, 14 displayed resistance to neutralization yet showed some level of binding with four to six N-MAbs.
When we examined the ability of each N-MAb to bind variant viruses at a high level (>f70~ of wild-type binding) despite a significant inability to neutralize them (eightfold or higher neutralizing titre compared with wild-type virus), 56~o (9/16) of variants possessing this level of resistance to neutralization by 30E10/All still bound this N-MAb with high efficiency. Results for the remaining N-MAbs were: 31D8/A1, 50~o (8/16); 31A2/D2, 21~ (3/14); 30E6/G4, 21~o (4/19); 30E3/F4, 15~ (2/13); 9J3/G6, 0~ (0/10). To determine whether these examples of significant binding despite resistance to neutralization were restricted to particular variant pools, the reactions of heterologous N-MAbs with each of the six pools were analysed. No virus variants within the E6 pool displayed ~> 70% N-MAb-binding efficiency and a concentration of N-MAb for neutralization eightfold or higher than that of wild-type virus. However in each of the remaining pools at least one variant displayed these properties with one or more of the heterologous N-MAbs. Two variants in particular met the binding and neutralization criteria with a majority of heterologous N-MAbs. Variant E3.D fulfilled these criteria with N-MAbs 31A2/D2, 30E10/All and 31D8/A1 and also exhibited a 50% binding efficiency with 30E6/G4 despite a high level of resistance to neutralization by it (32 times the wild-type neutralization titre). Variant A2. B displayed a high level of resistance to neutralization (32 times the wild-type titre) by its homologous N-MAb and by all other N-MAbs tested except 9J3/G6. All heterologous N-MAbs showed wildtype binding levels with A2. B and the homologous NMAb, 31A2/D2, bound with 80~ wild-type efficiency. For a few reactions between variants and N-MAbs, severely reduced binding levels were observed despite a slight reduction or none in the ability of the N-MAb to neutralize the variant compared to wild-type virus (e.g. 30E3/F4 with E6.F and 30E3/F4 and 30E6/G4 with J3.F). This phenomenon is also seen in results from similar studies presented by others (McCahon et al., 1989) and is commented on by Blondel et al. (1986) . However no explanation was provided in either study. Our interpretation of these data is that particular protein conformations displayed by certain variants predispose the virus to effective neutralization by a minimum amount of N-MAb binding to a critical epitope. Icenogle et al. (1983) have provided evidence for a similar minimal N-MAb requirement for poliovirus neutralization in addition to a 'multi-hit' phenomenon.
Reaction of variants with polyclonal antiserum
To determine the importance of the N-MAb-defined epitopes in a natural host, a comparison was made of the efficacy with which a bovine polyclonal anti-BV-1 (Aust) serum neutralized wild-type virus and the 25 variants. All variants displayed resistance to neutralization by this antiserum compared to wild-type virus (Fig. 3) . Several variants in the D8, E3 and A2 pools required at least 64 times more antibody to achieve neutralization. These results indicated that not only are these neutralization epitopes recognized in cattle but also that the majority of neutralizing anti-BTV-1 antibodies in bovine antiserum are directed toward them.
Discussion
Six N-MAbs to BTV-1 (Aust), at least four of which were specific for the outer coat protein VP2, were isolated in this study (Table 1 ). The neutralizing abilities and binding properties of these N-MAbs, plus another isolated previously (9J3/G6; White et al., 1985) , with BTV-1 (South Africa) and heterologous Australian and South African BTV serotypes (Tables 1 and 2) indicated that at least five unique neutralizing epitopes exist on the virus. N-MAb 9J3/G6 bound and neutralized only BTV-1 (Aust). N-MAb 30E6/G4 failed to neutralize BTV-1 (South Africa) but showed some binding to it and to seven other BTV serotypes. N-MAbs 30E3/F4, 31A2/D2 and 31D8/A12 showed similar but not completely analogous binding patterns. Unlike 30E3/F4 and 31A2/D2, however, 31D8/A12 failed to neutralize BTV-1 (South Africa) and was the only N-MAb capable of reacting in the Western blot test (Table 1 ; Fig. 1 ). N-MAbs 31D8/A1 and 30E10/All appeared to describe the same epitope based upon their near identical reaction values in Table 2 . However analysis of the reactions of the N-MAbs with pools of neutralization-escape variants of BTV-1 (Aust) produced using six of them, indicated that the seven N-MAbs defined distinct, yet interactive epitopes (Fig. 2) . That six of these epitopes were not maintained following SDS treatment in Western blotting (Table 1) indicates there may be conformational requirements for their individual expression. The ability of NMAb-selected variants to resist neutralization by a bovine polyclonal antiserum raised to BTV-1 (Aust) (Fig.  3) indicated that the N-MAb-defined epitopes are immunodominant in a natural host and may constitute part of a single, major neutralization domain on the virus.
The high level of conservation of all the N-MAbdefined epitopes (except 9J3/G6) across the BTV serogroup (Table 1) , especially for serotypes was surprising given the failure of the N-MAb panel to neutralize heterologous serotypes. These results suggested that serotype variation in BTV may have resulted at least in part from changes in the outer coat of the virus which modulate the conformation of VP2 to permit presentation of conserved epitopes in a non-neutralizing but still accessible manner. Thus variable regions identified from comparisons of the amino acid sequence of the VP2 proteins from different serotypes (Ghiasi et al., 1987) may represent either potential epitopes to which N-MAbs bind, or regions which determine protein conformation and consequently the involvement in virus neutralization, of highly conserved epitopes on the VP2 protein.
Analysis of the interactions between N-MAb-selected neutralization-resistant variants and both homologous and heterologous N-MAbs revealed that N-MAbdefined epitopes in a large number of variants remain able to bind antibody despite resisting neutralization (Fig. 2) . For example, more than half of the variants which required at least eight times more of N-MAbs 30E10/All and 31D8/A1 to affect neutralization compared with wild-type virus, still bound these N-MAbs at levels >~70~ of that displayed by neutralizationsensitive wild-type virus. Identification of amino acid alterations present in some of the variants have indicated one (Gould et al., 1988) or, on rare occasions, two (A. R. Gould, unpublished data) amino acid changes between the VP2 sequences of wild-type and variant viruses.
Thus alterations in the topography of the virus outer coat may occur as a result of a very small number of amino acid changes. Therefore, in addition to point mutations within neutralizing epitopes, antigenic drift to new serotypes may involve conformational changes in VP2 which affect the orientation, but not the structural integrity of several neutralizing epitopes. It was therefore of interest to investigate whether any of the variants displayed N-MAb binding and neutralization resistance characteristics analogous to those shown by any of the heterologous BTV serotypes tested. Analysis of the data in Table 1 and Fig. 2 indicated that variant E3.D displayed properties similar though not identical to BTV-7, and variant A2. B resembled BTV-6, -8, -9, -10, -11 (South African) and BTV-21 in their reactions with the N-MAb panel. Variant E3.D did not bind its homologous N-MAb but bound N-MAbs 31A2/D2, 30E10/All and 31D8/A1 with ~>70~ wild-type efficiency while still needing an eightfold or higher concentration of these MAbs, compared to wild-type virus, for neutralization. This variant also exhibited 50 wild-type binding efficiency with 30E6/G4 whilst possessing a high level of resistance to neutralization by it (32 times the titre required to neutralize wild-type virus). BTV-7 was the only heterologous serotype which exclusively bound the same four N-MAbs. It bound 30E6/G4 and 30E10/AI 1 at very similar levels to E3.D (40~o and 70~o of wild-type binding level respectively) and 31A2/D2 and 31D8/A1 at more reduced levels compared to E3. D binding (30~ and 50~ of wild-type binding level respectively). Variant A2. B had the same high level (32-fold) of resistance to neutralization by its homologous N-MAb and by four of the other five NMAbs tested. All heterologous N-MAbs showed wildtype binding levels with this variant, and the homologous N-MAb 31A2/D2 bound with 80~ wild-type efficiency. A similar ability to bind five of the N-MAbs was displayed by BTV serotypes 6, 9, 10, 11 and 21, and in particular BTV-8 which bound all N-MAbs except 9J3/G6 with ~>80~ wild-type efficiency. However neither E3.D or A2.B represented, de facto, another heterologous BTV serotype, as both were neutralized as effectively as wild-type virus by N-MAb 9J3/G6. No other BTV serotype tested bound this N-MAb (Table 2) . Despite this one significant difference, the fact that otherwise these two variants displayed similar properties to some other heterologous BTV serotypes, suggested that changes in regions which influence the conformation of VP2 may be part of the natural processes involved in escape from neutralization and hence the generation of new BTV serotypes. In addition, the exposure of BTV particles to the full spectrum of host antibodies raised to virus surface epitopes (both neutralizing and nonneutralizing) could be expected to have effects on protein conformation (or block sites by steric hindrance) which could in turn affect the properties of individual MAbdefined neutralization epitopes. This potential phenomenon could account for the inability of polyvalent antisera to each of BTV-2 and -13 to neutralize respective heterologous virus preparations despite the presence of a N-MAb-defined neutralizing epitope on the VP2 protein of both serotypes (Ristow et al., 1988) .
